Page 1

Abbott EXCEPTIONAL GROWTH , EXCEPTIONAL YEAR $ 10.7 + 28.4 % ¹ billion on organic basis * * Organic Jan. 27 , NAVICA $ 4.3B DIAGNOSTICS DEVICES $ 1.9B 1. On a GAAP earnings per full - year + Find important DIAGNOSTICS FOURTH - QUARTER 2020 NUTRITION SALES WORLDWIDE FIRST RAPID HANDHELD BLOOD TEST FOR CONCUSSIONS cause actual results may affect SALES PERFORMANCE ACROSS ABBOTT NUTRITION FDA clearance for 15 - minute blood test to help evaluate mild traumatic brain injury , commonly known as concussion CARDIOVASCULAR NEW PEDIALYTE PRODUCTS Expanded Pedialyte® product portfolio with four new products : Pedialyte with Immune Support , Pedialyte Sport , Pedialyte Organic and Pedialyte Electrolyte Water with Zero Sugar $ 34.6 + 9.8 % ² billion on organic basis * Exp PIPELINE ADVANCES ACROSS OUR DIVERSE BUSINESSES IN 2020 REMOTELY CONNECTING DOCTORS AND PATIENTS share 2021 of $ 1.26 primarily related safety information about ABBOTT.COM 1407 AT LEAST $ 5.00 35 Abbott's operations FULL - YEAR 2021 GUIDANCE ADJUSTED DILUTED EPS3 NEUROMODULATION Report on Form ► NeuroSphere ™ myPath ™ digital health app will allow chronic pain patients to track , analyze and report pain relief and general well - being associated with therapy during neurostimulation trial period App connects patients to physicians with real - time data access FORWARD - LOOKING STATEMENTS Some statements in this news release may forward - looking statements are subject to to basis , fourth - quarter Abbott sales increased 28.7 % . from continuing operations FULL - YEAR 2020 SALES WORLDWIDE differ materially are FOURTH - QUARTER AND FULL - YEAR 2020 FINANCIAL RESULTS to intangible under GAAP of at least $ 3.3B I - STAT Alinity from those indicated 1A , C Ats $ 1.1B REFLECTING GROWTH OF MORE THAN MEDICAL DEVICES ESTABLISHED PHARMACEUTICALS I - STAT Alinity Abbott MARKET EXPANSION WITH KEY APPROVALS ▸ Expanded Medicare ( CMS ) reimbursement for MitraClip , significantly increasing insurance coverage ► FDA approval for HeartMate 3 ™ M heart pump for pediatric patients battling advanced heart failure NEW ! + 1DOCTOR RECOMMENDED #BRAND FOR HYDRATION ELECTROLYTE DOMIDE ABBOTTNEWS Pedialy WITH IMMUN SUPPOR ZINC | VITAMI & OTHER KEY NUTR 0.490 MIXED BERRY NATALLATION RAVNET V MY DATA 33 % MORE ELECTROLYTES Right Leg Left Log COPENT RELE 80 % the FreeStyle Libre portfolio : www.freestylelibre.us/safety-information . T INNOVATION FOR ACCESS ▸ New product launches : FDA clearance for FreeStyle® Libre 2+ for adults and kids 4+ , VERSUS PRIOR YEAR CE Mark for FreeStyle Libre 3 , CE Mark for FreeStyle Libre 3 and Libre Sense Glucose Sport Biosensor 9:41 2 Pain Relief 80 % impreverunt ▸ Announced long - term support for American Diabetes Association health equity initiative to advance access to care and technology for underserved diabetes communities STARTING UP DIABETES CARE 8 2. On a GAAP $ 3.74 , reflecting growth of at least amortization , expenses associated with acquisitions , restructuring and cost sales growth excludes impact of foreign exchange . For full financial data and reconciliation of non - GAAP measures , please see 2021 , available at www.abbottinvestor.com . in our Quarterly any revisions to forward - looking statements as a result of subsequent events or developments , except as required by law . AFT BAR Abbott PAIN RELIEF PEARELING #BRAND FOR HYDRATION 0.49 02 ( 41 ) PACKETS / PUTRAL PELNET WIL 25402 ( 846 ) PUNCH Pedialyte WITH IMMUNE SUPPORT + ZINC I VITAMIN C & OTHER KEY NUTRIENTS NewSpheremy Pat RESOURCES Download SNAPSHOT a les beter over 33 % MORE ELECTROLYTES ! ELECTROLYTE POWDER RESOURCES ► ABBOTT in ABBOTT ati Share 4500 Day 3 ove jou tround keep Good morning , Jenn You have below . basis , full - year Abbott sales increased 8.5 % . 3. Abbott projects full - year 2021 diluted 50 % versus the prior year . Abbott forecasts specified items for the reduction initiatives and other net expenses . WA Kurtha iss what the mind be forward - looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these risks and uncertainties , including the impact of the COVID - 19 pandemic on Abbott's operations and financial results , that may in the forward - looking statements . Economic , competitive , governmental , technological and other factors that discussed in Item " Risk Factors " in our Annual Report on Form 10 - K for the year ended Dec. 31 , 2019 and in Item 1A , " Risk Factors " 10 - Q for the quarter ended March 31 , 2020 , and are incorporated herein by reference . Abbott undertakes no obligation to release publicly our press release dated ABBOTTGLOBAL f ABBOTT